Navigation Links
AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
Date:4/30/2008

o placebo-controlled trials investigated two formulations of cetrorelix to determine the extent and duration of symptomatic improvement and to select the interval between courses for an intermittent treatment scheme.

Trial Design

Trial-A compared 3 regimens of subcutaneous cetrorelix acetate with placebo (35 patients/group): 5mg x 4, 7 days apart; 10mg x 4, 7 days apart; and 10mg x 2, 14 days apart.

Trial-B compared 4 regimens of intramuscular cetrorelix pamoate with placebo (30 patients/group, 14 days between doses): 30mg x 2; 30mg x 3; 60mg and 30mg; 60mg x 2. Patients were followed up for 20 and 28 weeks after the first dose in Trial-A and B, respectively. International Prostate Symptom Score (I-PSS) primary endpoint was assessed in 4-weekly intervals; other endpoints included uroflow, prostate size, and testosterone levels.

Results

In both trials, 4 weeks after first dose, all regimens showed a statistically significant reduction in I-PSS from baseline; at week 12, the difference from placebo was statistically significant for all dosage regimens except the 30mg x 2 in Trial-B (Trial-A: p<0.05; Trial-B: p <0.001). Generally, the improvement in I-PSS, which tended to be better in the higher dosage groups of Trial-B (reduction of 5-7 points, i.e. 30%-40%), was maintained throughout the follow-up period and was paralleled by an improvement in uroflow. A slight, dose-dependent reduction in prostate size was noticed in both trials. All dosage regimens tested were well tolerated, and none were associated with sexual side effects.

Conclusions

In both studies, a prolonged duration of effect extending far beyond the end of the short-term treatment course was observed. For the long-term management of BPH patients, the results from both studies support a 6-month interval between subsequent treatment courses.

About Cetrorelix

Cetrorelix is part of AEterna Zentaris' LHRH antagonist therapeutic approach that has de
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Announces Changes to its Management Team
4. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
5. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
6. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
7. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
10. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
11. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 2015  DuPont (NYSE: DD ) announced ... Conference held today in New York ... discussed strategy, progress and plans to accelerate growth ... and growing the company,s leading position in high-value advanced ... priority for DuPont. Discussing the company,s Advanced ...
(Date:3/5/2015)... 5, 2015   HX360 today announced that ... HX360 Innovation Challenge competition. These companies, selected ... be chosen as one of four finalists to present ... system executives and venture capitalists during the Innovation Challenge ... place at the 2015 HIMSS Annual Conference & Exhibition, ...
(Date:3/5/2015)... Minn. (PRWEB) March 05, 2015 Plant ... Pasadena this summer at the Annual Meeting of The ... starting to be released online now at APSnet.org/meet ... announced for the meeting, to be held August 1-5, ... announced Special Sessions, Field Trips, Workshops, and committee meetings, ...
(Date:3/5/2015)... Bi-Biomics today announced a discovery ... additive. The improvement in histological quality provided the ... in all daughter cells. , After processing with ... analyzed at 1000-1600x using light microscopy. Phylogenetic ... all daughter cells displayed predominant binary features --- ...
Breaking Biology Technology:DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 2DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 3DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 4HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4American Phytopathological Society Announces Annual Meeting Daily Schedule 2
... (GeneXP Biosciences Inc.) , ... Efficient and cost-effective method for synthesizing , ... Increase throughput by >10-fold , ... , , ...
... , Ambion scientists have engineered a ... improve production of full-length cDNA. This engineered reverse transcriptase, , ... href="http://www.ambion.com/catalog/CatNum.php?2048">ArrayScript , ... cDNA than wild type RTs, and rivals even the newest engineered RTs on ...
... Data Generated From Both mRNA , ... Clustering analysis is commonly used for ... of complex data and a method for measuring , similarity ... microarray data are: Hierarchical, K-means and Self-organizing map. In this ...
Cached Biology Technology:Automated RNA Amplification for Arrays 2Automated RNA Amplification for Arrays 3Automated RNA Amplification for Arrays 4Automated RNA Amplification for Arrays 5ArrayScript RT: Maximize Yields of Full-length cDNA 2ArrayScript RT: Maximize Yields of Full-length cDNA 3Analysis of Microarray Data 2Analysis of Microarray Data 3Analysis of Microarray Data 4Analysis of Microarray Data 5Analysis of Microarray Data 6Analysis of Microarray Data 7
(Date:2/12/2015)...   MedNet Solutions , a global life ... systems, has recently bolstered its iMedNet™ ... iMedNet as the eClinical solution of ... consultants.  Building on the Program,s existing benefits (including ... co-marketing opportunities), MedNet,s new and improved program provides ...
(Date:2/10/2015)... Mass., Feb. 10, 2015  Alere Inc. (NYSE: ... its financial results for the quarter ended December ... Officer and President of Alere said, "We made ... Alere as the global leader in rapid diagnostics ... the Alere Health divestiture in early January enabled ...
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35
... 2008) -- Cell Press has been chosen by ... journal from January 2009. The Biophysical Society ... Journal content and that of the Cell Press ... and Structure. , For more than 50 years ...
... . , Iron is vital to human life; ... that makes our blood red and supplies our cells with ... thought that iron deposits in the brain contribute to certain ... Alzhiemers. A malfunction of the blood transporter transferrin may be ...
... new modeling approach to estimate sea ice thickness. This ... The model was developed by scientists with ... Sciences, Moscow. Using this new technique, the ... to 2003. Results showed that average ice thickness and ...
Cached Biology News:Cell Press announces new partnership with the Biophysical Society 2Rusty worms in the brain 2New method to estimate sea ice thickness 2
... Y2 Receptor antiserum This NPY Y2 ... level and is currently being characerized in brain. ... and mouse and appears to work better on ... rat. For full characterizarion in dorsal root ganglion ...
... This adapter allows ... (AB-0800 and AB-1000) PCR ... in the ABI PRISM® ... contact ABgene® for information ...
... Synucleins are small, soluble proteins expressed ... tumors. The family includes three known proteins: ... The alpha and beta synuclein proteins are ... are seen mainly in presynaptic terminals. ...
... antibody is specific for human cardiac troponin subunit ... Ca-binding signals responsible for contraction of cardiac muscle. ... complex in human cells. It also cross-reacts with ... Antigen: Highly purified human cardiac ...
Biology Products: